Judit Hársing
YOU?
Author Swipe
View article: Combined corticosteroid and etanercept therapy in toxic epidermal necrolysis
Combined corticosteroid and etanercept therapy in toxic epidermal necrolysis Open
The authors present the case of a 34-year-old female patient hospitalized for lamotrigine-induced toxic epidermal necrolysis (TEN). The initial clinical presentation suggested TEN with cutaneous, oral, and genital mucosal involvement, whic…
View article: Real-World Experience with Cemiplimab Treatment for Advanced Cutaneous Squamous Cell Carcinoma—A Retrospective Single-Center Study
Real-World Experience with Cemiplimab Treatment for Advanced Cutaneous Squamous Cell Carcinoma—A Retrospective Single-Center Study Open
Background: The systemic treatment of advanced cutaneous squamous cell carcinoma (cSCC) has seen significant developments in recent years. The anti-PD1 inhibitor cemiplimab has demonstrated efficacy in clinical trials, but real-world data …
View article: Skin affecting adverse events of immunotherapies for the treatment of malignancies
Skin affecting adverse events of immunotherapies for the treatment of malignancies Open
As the fifth pillar of antitumor treatment, immunotherapies have brought a significant breakthrough in oncology. Immune checkpoint inhibitors have been shown to be the most effective modality among immunotherapies by stimulating the antitu…
View article: Anti-PD-1 Monotherapy in Advanced Melanoma—Real-World Data from a 77-Month-Long Retrospective Observational Study
Anti-PD-1 Monotherapy in Advanced Melanoma—Real-World Data from a 77-Month-Long Retrospective Observational Study Open
Real-world evidence plays an important role in the assessment of efficacy and safety of novel therapies. The increasing use of immune checkpoint inhibitors (ICIs) in patients with advanced melanoma has led to notably improved clinical outc…
View article: Proteogenomics Reveals how Metastatic Melanoma Modulates the Immune System to Allow Immune Evasion
Proteogenomics Reveals how Metastatic Melanoma Modulates the Immune System to Allow Immune Evasion Open
Summary Malignant melanoma (MM) develops from the melanocytes and in its advanced stage is the most aggressive type of skin cancer. Here we report a comprehensive analysis on a prospective cohort study, including non-tumor, primary and met…
View article: Frequent KIT mutations in skin lesions of patients with BRAF wild-type Langerhans cell histiocytosis
Frequent KIT mutations in skin lesions of patients with BRAF wild-type Langerhans cell histiocytosis Open
Langerhans cell histiocytosis (LCH) is characterized by mutations of the RAS-RAF-MAPK signaling pathway. We analyzed MAP2K1, NRAS and KIT mutation incidence in skin lesions of BRAF wild-type (wt) LCH patients. We evaluated the occurrence o…